286 related articles for article (PubMed ID: 30407786)
1. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW
ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786
[TBL] [Abstract][Full Text] [Related]
2. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Dec; 77():318-330. PubMed ID: 30463049
[TBL] [Abstract][Full Text] [Related]
4. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.
Poonia P; Sharma M; Jha P; Chopra M
Mol Divers; 2023 Oct; 27(5):2053-2071. PubMed ID: 36214962
[TBL] [Abstract][Full Text] [Related]
6. Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
Zeb A; Son M; Yoon S; Kim JH; Park SJ; Lee KW
Comput Struct Biotechnol J; 2019; 17():579-590. PubMed ID: 31073393
[TBL] [Abstract][Full Text] [Related]
7. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
[TBL] [Abstract][Full Text] [Related]
8. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
9. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
Ruzic D; Djokovic N; Nikolic K
Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
[TBL] [Abstract][Full Text] [Related]
10. An assessment of crucial structural contributors of HDAC6 inhibitors through fragment-based non-linear pattern recognition and molecular dynamics simulation approaches.
Banerjee S; Jana S; Jha T; Ghosh B; Adhikari N
Comput Biol Chem; 2024 Jun; 110():108051. PubMed ID: 38520883
[TBL] [Abstract][Full Text] [Related]
11. Combined comparative molecular field analysis, comparative molecular similarity indices analysis, molecular docking and molecular dynamics studies of histone deacetylase 6 inhibitors.
Sharma M; Jha P; Verma P; Chopra M
Chem Biol Drug Des; 2019 May; 93(5):910-925. PubMed ID: 30667160
[TBL] [Abstract][Full Text] [Related]
12. HDAC6 ZnF UBP as the Modifier of Tau Structure and Function.
Balmik AA; Chidambaram H; Dangi A; Marelli UK; Chinnathambi S
Biochemistry; 2020 Dec; 59(48):4546-4562. PubMed ID: 33237772
[TBL] [Abstract][Full Text] [Related]
13. 5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
Lee HY; Fan SJ; Huang FI; Chao HY; Hsu KC; Lin TE; Yeh TK; Lai MJ; Li YH; Huang HL; Yang CR; Liou JP
J Med Chem; 2018 Aug; 61(16):7087-7102. PubMed ID: 30028616
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation.
Kumbhar N; Nimal S; Barale S; Kamble S; Bavi R; Sonawane K; Gacche R
Sci Rep; 2022 Feb; 12(1):1712. PubMed ID: 35110603
[TBL] [Abstract][Full Text] [Related]
15. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
[TBL] [Abstract][Full Text] [Related]
16. Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6.
Sixto-López Y; Bello M; Correa-Basurto J
J Biomol Struct Dyn; 2019 Nov; 37(18):4701-4720. PubMed ID: 30558483
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
[TBL] [Abstract][Full Text] [Related]
18. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
Kashyap K; Kakkar R
J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
[TBL] [Abstract][Full Text] [Related]
19. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
